Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting
FOSTER CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.
- FOSTER CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.
- We are excited about these clinical results as they not only corroborate, but expand upon, those of our three other validation trials.
- That is, all patients predicted to respond clinically actually did while those patients predicted not to respond, did not.
- A PPV of 100% indicates, for example, that a clinical trial selectively enrolling predicted clinical responders would result in a 100% response rate.